The combination developed by the
scientists consists of a modified
version of polyethylene glycol
and a reactive block copolymer
of poly [(2-dimethylamino)
ethyl methacrylate] and poly
(N-isopropyl acrylamide). The
two compounds react and form a
hydrogel in less than four minutes.
APOLLO & RMS REGROW BRING
FIRST OF ITS KIND CELL THERAPY
FOR ORTHOPEDIC PATIENTS TO
INDIA
Apollo Hospitals has partnered
with RMS REGROW, the first
‘Make in India’ Company in Cell
Therapy Technology, to offer two
new Regenerative Medicine Cell
Therapy products- Ossron™ and
Chondron® for bone and cartilage
problems, respectively. The two
products will address unmet clinical
needs in the orthopaedic market
with respect to sports injuries,
accidents and alternate to hip
replacements
and knee
replacements
for a young
arthritic knee.
In an exclusive
tie up between
Apollo Hospitals and RMS Regrow,
the treatment therapy will be
made available across all Apollo
Hospitals, Apollo Spectra Hospitals
and Apollo clinics in India.
The joint statement by the
companies stated that the
Ossron and Chondron are the
results of a dedicated research
team at REGROW. The two
products are innovative
proprietary and patented
technology which has been
developed for both the products
following the regulatory guidelines.
Through several clinical trials and
evaluation studies over 8 years, the
company has achieved the market
authorization for the two cell
therapy products.
who is one of the researchers
involved in the development
mentioned, “The new hydrogel
also leaves no byproduct. Hence,
it is biocompatible. Further, it
is biodegradable making it well
suited for wound healing and tissue
regeneration”.
As an exclusive offering, Apollo
Hospitals will create a platform
for orthopaedic doctors to practice
Regenerative Medicine efficiently by
conducting live surgical workshops,
CME’s for doctors and conferences
(national and international).
BIOVOICENEWS.COM
69